Personalised neoantigen vaccines and CAR-T cell therapy are both for the same cancer but work differently. The former is recognised by T cells for altered peptides; CAR-T cells are
A randomized controlled trial with a clear efficacy signal (higher ORR and pCR with dual-targeted therapy) and favorable tumor marker reduction, but with surrogate endpoints and no hard clinical outcomes reported.